Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC

Wehler, T. and Wehler, B. and Atmaca-Dirik, H. and Schulz, C. and Grohe, C. and Topsch, J. and Ehrlich, A. (2021) Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC. In: European Lung Cancer Virtual Congress ELCC 2021, 25 March 2021 - 27 March 2021, Virtual.

Full text not available from this repository.

Item Type:	Conference or Workshop Item (UNSPECIFIED)
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Innere Medizin II
Depositing User:	Petra Gürster
Date Deposited:	11 Jan 2023 10:37
Last Modified:	11 Jan 2023 10:38
URI:	https://pred.uni-regensburg.de/id/eprint/46961

Actions (login required)

View Item